Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
86 studies found for:    hepatitis c | Abbvie [Lead]
Show Display Options
Rank Status Study
1 Active, not recruiting A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection
Conditions: Hepatitis C Virus Infection;   Human Immunodeficiency Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis and Non-cirrhotics
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin (RBV)
2 Recruiting Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
Condition: Chronic Hepatitis C
Intervention:
3 Active, not recruiting Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
Condition: Chronic Hepatitis C
Intervention:
4 Completed A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   Compensated Cirrhosis
Interventions: Drug: ABT-493;   Drug: ABT-530;   Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin (RBV)
5 Recruiting A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
Conditions: Hepatitis C Virus Infection;   Human Immunodeficiency Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis and Non-cirrhotics
Intervention: Drug: ABT-493/ABT-530
6 Active, not recruiting Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
Conditions: Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 1a
Interventions: Drug: ombitasvir/ABT-450/ritonavir;   Drug: dasabuvir;   Drug: ribavirin
7 Active, not recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
Conditions: Chronic Hepatitis C Virus;   Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530;   Drug: Ombitasvir/paritaprevir/ritonavir
8 Active, not recruiting A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
Conditions: Chronic Hepatitis C;   Cirrhosis;   Hepatitis C Virus
Interventions: Drug: Ombitasvir;   Drug: Paritaprevir;   Drug: Ritonavir;   Drug: Dasabuvir;   Drug: Ribavirin
9 Active, not recruiting A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
Conditions: Chronic Hepatitis C;   Decompensated Cirrhosis;   Hepatitis C Virus
Interventions: Drug: ABT-450/ritonavir/ABT-267;   Drug: ABT-333;   Drug: Ribavirin
10 Active, not recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
Conditions: Chronic Hepatitis C Virus;   Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530;   Drug: Sofosbuvir;   Drug: Ribavirin
11 Active, not recruiting A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
Conditions: Hepatitis C Infection;   Hepatitis C Virus
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir;   Drug: dasabuvir
12 Active, not recruiting A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
Conditions: Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 1
Interventions: Drug: ABT-450/r;   Drug: ABT-267;   Drug: pegylated interferon alpha-2a (pegIFN);   Drug: Ribavirin (RBV)
13 Recruiting Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
Condition: Chronic Hepatitis C Virus
Intervention:
14 Recruiting Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania
Condition: Chronic Hepatitis C
Intervention:
15 Active, not recruiting Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Intervention:
16 Recruiting Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS
Condition: Chronic Hepatitis C
Intervention:
17 Recruiting Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
Condition: Chronic Hepatitis C
Intervention:
18 Recruiting The Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
Condition: Chronic Hepatitis C
Intervention:
19 Completed
Has Results
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: ABT-333;   Other: Placebo for ABT-333;   Drug: Pegylated interferon;   Drug: Ribavirin
20 Active, not recruiting The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
Condition: Hepatitis C Virus
Intervention: Drug: ABT-493/ABT-530

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years